European Commission Approves New Alopecia Areata Treatment

The European Commission has approved AbbVie's RINVOQ (upadacitinib) for severe alopecia areata in adults and adolescents aged 12 and older. This regulatory action, supported by Phase 3 trial data showing significant scalp hair regrowth, introduces a new therapeutic option for patients across the EU. It addresses an unmet medical need for individuals with this autoimmune condition.